Advertisement

The Evolution of Vitiligo Treatment: From Steroids and Broad Immunosuppression to Targeted JAK Inhibition

When Maui, HI-based Dermatologist George Martin, MD, first started out in 1985, vitiligo was considered an orphan disease, but times have changed. “The evolution over the past 40-plus years has been nothing but astounding,” he says in this episode of Prescribing Hope in Vitiligo. Calling the development and approval of topical ruxolitinib (Opzelura, Incyte) for vitiligo, a “total game-changer” and proof that the Janus kinase/signal transducers and activators of transcription (JAK/STAT) signaling pathway was a major player in the pathogenesis of vitiligo, Dr. Martin discusses the importance of managing patient expectations during the repigmentation process.

Keeping the Color: Maintenance Strategies After Vitiligo Repigmentation
Hope on the Horizon: Ushering in the New Era in the Management of Vitiligo
Of Patients and Patience in Vitiligo: The Importance of Managing Treatment Expectations
A Deep Dive Into Vitiligo and Its Associated Comorbidities
It’s a Marathon, Not a Sprint: Achieving Repigmentation in Vitiligo With Topical JAK Inhibitors
Advertisement

About This Educational Video Series

This educational video series provides expert commentary on the current treatment landscape for patients with vitiligo.